A randomized, double-blinded, placebo-controlled study on the effects of adalimumab intralesional intestinal strictures of Crohn's disease patients
Phase of Trial: Phase III
Latest Information Update: 27 Mar 2019
Price : $35 *
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 30 Nov 2018 Status changed from recruiting to discontinued.
- 04 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2019.
- 04 Apr 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2019.